



Atsuhiko TOYAMA¹, Daisuke KAWAKAMI¹ (1) Shimadzu Corporation, Kyoto, Japan.

Introduction

- Although LC-MS/MS analysis manifests high repeatability in measurement, overall reproducibility of an assay is compromised by errors associated with manual sample pretreatment. This also hinders standardization of assay across multiple laboratories.
- Derivatization of is employed in LC-MS/MS analysis to achieve better chromatographic separation or to enhance favorable detection in MS. However, it involves series of reagent addition and vortexing, making the pretreatment prone to errors and hence low reproducibility.
- In this investigation, we evaluated tested whether or not automated sample preparation device can be employed to carry out complex sample pretreatment procedures, such as required for chemical derivatization. For model experiment plasma metanephrine and normetanephrine was derivatized by reductive amination as shown in Fig. 1 to improve reversed phase column retention.




Fig. 1 Target compounds and their derivatization products obtained by reductive amination using butanal as aldehyde and 2-picolineborane as reducing agent.

Methods

Sample and reagents

Commercially available pooled plasma was used as sample matrix. IS solution (1 ppb of standard compounds and deuterated internal standard in water), Reagent 1 (butanal/acetic acid = 25:75), Reagent 2 (7% 2-picolineborane in EtOH, w/v) and Reagent 3 (5% aq. ammonia) were prepared in 6 mL glass container and placed in CLAM-2000 as reagent reservoir.

Automated sample preparation

Fig. 2 illustrates the general appearance of the instrument setting, with CLAM-2000 connected to LCMS-8060 to comprise an integrated "turnkey" type analyzer system. The pretreatment steps carried out are shown in the flow chart that include 5 steps of reagent addition and 4 steps of vortexing. The procedure completes within 6 minutes, and it can be ran parallelly with LC-MS/MS measurement so resulting in no wait-time between sequential analyses.




Fig. 2 Appearance of CLAM-LCMS system, and the pretreatement steps carried out for derivatization.

Analytical conditions

Shown below are the list of target compounds, their MRM transitions and the HPLC condition for LC/MS/MS analysis.

Compound	MW	Precursor <i>mlz</i> (derivatized)	Product <i>m/z</i>	CE (V)
Metanephrine (MN)	197.23	254.15	236.15	-14
MN-d3	200.23	257.15	154.10	-21
Normetanephrine (NMN)	183.20	296.20	278.20	-17
NMN-d3	186.20	299.20	154.10	-21

Column	: Shimpack GISS C18 (100 mm x 2.0 mm, 3 μm)	
Mobile phase A	: 0.1% formic acid in water	
Mobile phase B	: Methanol	
Flow rate	: 0.4 mL/min	
Column temp.	: 40 °C	
Injection volume	: 1 µL	

Results




Fig. 3 MRM chromatograms of MN and MN-d3 spiked in control plasma at 1 ng/mL concentration.

Quantitation of plasma metanephrine and normetanephrine by derivatization using an integrated LC-MS/MS analyzer equipped with fully-automated sample preparation device

Two consecutive measurement of MN and NMN were made, each starting fresh sample pretreatment. High intensity signal was detected demonstrating that direct one-pot derivatization in plasma was successful, and that there was minimal difference between the two runs. Under the given condition, NMN showed higher signal; derivatization condition was likely more favorable for NMN than for MN.





Fig. 4 MRM chromatograms of NMN and NMN-d3 spiked in control plasma at 1 ng/mL concentration.



Conclusion

- Although still preliminary, the experiment clearly demonstrated that complex sample pretreatment such as derivatization was greatly facilitated by automation by CLAM-2000.
- Due to sequential pretreatment scheme, the incubation times and vortex conditions were kept constant, thus contributing to exceptional inter-run reproducibility for a derivatization method.
- In-depth evaluation and optimization requires the use of synthetic standards for the derivatized compounds for future work.

Disclaimer: The products and applications in this presentation are intended for Research Use Only (RUO). Not for use in diagnostic procedures. Not available in China.





Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®".

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "@". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.